TQB3909 + azacitidine

TQB3909 + azacitidine is an investigational **combination therapy** currently under clinical evaluation for the treatment of **myeloid malignancies**, specifically targeting diseases such as **acute myeloid leukemia (AML)** and **myelodysplastic syndromes (MDS)**. TQB3909 is a **B-cell lymphoma 2 (BCL-2) protein inhibitor** formulated as oral tablets, while azacitidine is an established hypomethylating agent and chemotherapy drug, typically administered by injection. Azacitidine works by incorporating into DNA and RNA to disrupt nucleic acid metabolism and inhibit DNA methyltransferase, leading to impaired DNA methylation and promoting anti-neoplastic activity. The combination aims to leverage azacitidine’s epigenetic modulation with the pro-apoptotic effects of BCL-2 inhibition, potentially leading to additive or synergistic anti-leukemic effects.[1][2][7][10]